The usage of dihydropyridine calcium-channel blockers (DCCBs) could also be related to worse renal outcomes for sufferers with diabetic kidney illness (DKD), even when used alongside present standard-of-care therapies, in keeping with analysis offered on the 2026 European Renal Affiliation Congress in Glasgow, Scotland.
The observational research analyzed information from 31,031 adults with kind 2 diabetes handled between 2016 and 2021, all of whom had been receiving each renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Of the total cohort, 39.2% had been additionally handled with DCCBs. Over a median follow-up of roughly 3.5 years, DCCB use was related to a 33% greater threat of main hostile kidney occasions (threat ratio, 1.33; 95% CI, 1.03-1.73), outlined as a 40% or higher decline in estimated glomerular filtration fee or development to end-stage kidney illness.
Lead research creator Timna Agur, MD, MSc, a senior nephrologist at Rabin Medical Middle and director of the nephrology outpatient clinics at HaSharon Hospital in Israel, mentioned in a press launch, “DCCBs are extensively used as second-line blood strain remedies in sufferers with DKD. Our findings elevate essential questions on whether or not these drugs are at all times the most suitable choice for sufferers already receiving fashionable kidney-protective therapies.”
The investigators instructed that DCCBs could contribute to ongoing kidney harm by rising intraglomerular strain. They posited that DCCBs preferentially dilate blood vessels that carry blood into the kidney’s filtering models, with out equally affecting the blood vessels that carry blood away. Notably, the elevated dangers of DCCB use persevered regardless of concomitant SGLT2 inhibitor use, as did the elevated threat for kidney illness development.
The authors emphasised that the findings are observational and don’t set up causality, calling for randomized trials to higher outline optimum antihypertensive methods in DKD.
 may be tied to worse renal outcomes in diabetic kidney disease (DKD), even used with standard care therapies.){kind=link}